A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte

Gene Therapy

Volumn 12, Issue 13, 2005, Pages 1049-1057

  Zhang, M ^a   Obata, C ^a   Hisaeda, H ^a   Ishii, K ^a   Murata, S ^b   Chiba, T ^b   Tanaka, K ^b   Li , Y ^a   Furue, M ^a   Chou, B ^a   Imai, T ^a   Duan, X ^a   Himeno, K ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

DNA vaccine; Melanoma; Ubiquitin proteasome pathway

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; DNA VACCINE; EPITOPE; HYBRID PROTEIN; NAKED DNA; PLASMID DNA; PROTEASOME; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; UBIQUITIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; KNOCKOUT MOUSE; LUNG METASTASIS; MELANOCYTE; MELANOMA; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUPPRESSOR CELL; SURVIVAL RATE; TISSUE DIFFERENTIATION; TUMOR IMMUNITY; VACCINATION;

ANIMALS; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE THERAPY; INTERFERON TYPE II; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; UBIQUITIN; VACCINES, DNA;

EID: 21744432189     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302490     Document Type: Article

References (36)

1. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-182.
2. Wang RF et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207-2216.
3. Weber LW et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998; 102: 1258-1264.
4. Overwijk WW et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188: 277-286.
5. Bowne WB et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 1717-1722.
6. Tüting T et al. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999; 6: 73-80.
7. Steitz J et al. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Therapy 2002; 9: 208-213.
8. Engelhard VH et al. Antigen derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002; 188: 136-146.
9. + cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987; 166: 182-194.
10. + CTL. J Immunol 2001; 167: 3687-3691.
11. Nishitani MA et al. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther 2002; 9: 156-163.
12. Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol Rev 1998; 163: 161-176.
13. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. In: Dixon FJ (ed). Advances in Immunology, Vol 80. Academic Press: Oxford, 2002, pp 1-71.
14. Kloetzel P-M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001; 2: 179-187.
15. Xiang R et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000; 97: 5492-5497.
16. Johnson ES, Ma PC, Ota IM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 1995; 270: 17442-17456.
17. Zhang M et al. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology 2004; 112: 567-574.
18. Murata S et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β. EMBO J 2001; 20: 5898-5907.
19. van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-693.
20. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-287.
21. Bloom MB et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-459.
22. Lindauer M et al. The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J Mol Med 1998; 76: 32-47.
23. Noppen C et al. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 2000; 87: 241-246.
24. Rock KL et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771.
25. Cerundolo V et al. The proteasome-specific inhibitor lactocystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol 1997; 27: 336-341.
26. Craiu A et al. Lactacystin and clasto-lactacystin b-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997; 272: 13437-13445.
27. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
28. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997; 71: 8497-8503.
29. Leitner WW et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathway. Nat Med 2003; 9: 33-39.
30. + T lymphocytes. Proc Natl Acad Sci USA 1999; 96: 2982-2987.
31. + hematopoietic progenitor cells. Int J Cancer 2000; 86: 385-392.
32. Bronte V et al. Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60: 253-258.
33. Sakai T et al. Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmaniamajor and Trypanosoma cruzi in mice. Immunology 2000; 99: 615-624.
34. Sakai T et al. Gene gun-based co-immunization of merozoit surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine 2003; 21: 1432-1444.
35. Nanni P et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 1998; 58: 1225-1230.
36. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185-192.